The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.
about
Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future.Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in malesPopulation-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysisCross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic VaccinesVLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirusA pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.Safety of human papillomavirus vaccines: a review.Human papillomavirus genotype prevalence in invasive vaginal cancer from a registry-based populationA vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types.Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK.Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis.Human papillomavirus genotype distribution in Czech women and men with diseases etiologically linked to HPVUpdate on prevention and screening of cervical cancer.HPV in HIV-Infected Women: Implications for Primary PreventionPerspective for prophylaxis and treatment of cervical cancer: an immunological approach.Meta-analysis on prevalence and attribution of human papillomavirus types 52 and 58 in cervical neoplasia worldwideEpidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future.Human papillomavirus infection in women with and without cervical cancer in Ibadan, NigeriaInclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease.Impact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach.Age-specific occurrence of HPV16- and HPV18-related cervical cancer.Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex tSystematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure.Aspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries.Papillomaviruses: Viral evolution, cancer and evolutionary medicineRandomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccineValidation of a low-cost human papillomavirus genotyping assay based on PGMY PCR and reverse blotting hybridization with reusable membranesHuman papilloma virus vaccines: Current scenarioPreclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa.Prevalence of type-specific HPV among female university students from northern Brazil.Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera.Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years).Laboratory and clinical aspects of human papillomavirus testingGenital HPV infection and related lesions in menDevelopment of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus.Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults.
P2860
Q24600011-78FDC62D-D667-4B9A-B329-058A1BAF3372Q24614644-E21EC4AF-8612-49B1-A952-24BE633DD23AQ28084924-D4E8716C-8952-4357-B6E4-3E4520961E75Q28085724-FD423EA4-149D-4755-8F77-8AC3D41D0C28Q28280059-694D7B0B-22D7-4FE8-A6D0-B4316FF3B7FCQ28741364-FB503745-42A7-409A-9ECC-6A2B69ACB4D7Q30573204-F3AD2F3B-1E79-4E5A-ACAD-36BC5E4849F1Q33162724-0DB6BE58-870D-4604-8AB9-2F3D69DA1F31Q33563955-BD0E045E-7B4E-4F98-98DA-B79E3DF3C9A4Q33572691-62FAE38C-9C73-429A-859B-1DC530970956Q33708098-FEB0CDCC-E91C-451F-AD12-4C6F32A99065Q33791312-99ED5950-D21B-4673-9946-A858DCCBE79EQ33963857-77CCF212-61B6-4259-B5C2-5A5BD8F09528Q34031269-7964A5E7-8EE0-45F3-AFDE-087CC5DE4E6DQ34033445-98DDED0B-8768-424A-A253-E2A0F2543CCFQ34181909-7998A502-2209-4841-95E0-F8C2C24BB246Q34207423-248E5CEF-CEC1-49E7-AA8C-3A7F09924824Q34267472-2B4CA823-FE5A-47B0-BBB7-092950F135E1Q34335370-AC053921-F370-4311-8CA4-79E2B1018F09Q34471165-90F6BEC3-0F0E-497D-BEF6-46C48C2EFF68Q34580293-FB3E01D1-2897-4392-9E42-0D987E3EDB8FQ34743370-5FF512CC-CE5E-4012-81DA-155A8336F0A1Q34979497-6EC51203-BBC0-4467-991B-5B73196955A9Q35013844-755438BA-423D-4B23-85F6-95AC7FA5C36BQ35021139-22973E8D-D206-4A45-8B49-6C0EE5C83D9CQ35111092-084191FC-22C6-460B-BA9E-789CE681D678Q35117498-35B8069B-1956-44DC-B6E5-28D8D5F6014DQ35166924-C542C5E4-AB56-496C-A239-054BBBE93E0AQ35191198-E945033E-9BE3-400D-BBD9-F71FBC23F412Q35273321-4F17D75C-51D3-49E2-9BC7-7C58BAEC4357Q35366075-7848EB9A-5769-4DDC-9ACE-198A0A110A2FQ35744303-6AF7FDA6-34EA-42AF-A38C-DCCE9DA690DAQ35858737-39128E7A-2AA6-46E8-8707-7BEC4DF37C6DQ35879158-ADCA0471-519D-489C-B2F4-4363684ABB46Q35985515-33DC9161-4C69-4E64-828C-E1CAD38E2DDCQ36256554-3E909C90-9BDF-4F9D-A31E-BBF625219428Q36311573-A59F742E-DEC1-49DC-B79A-299220D409DEQ36389950-415F4FEC-44EF-4FDD-84BA-EBE5328E31C2Q36846030-35A4041C-EB53-455D-9E40-C35FD8F3EF7CQ36977831-9DD0EC9D-000E-467C-B402-D8954066A371
P2860
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
The impact of quadrivalent hum ...... active women aged 16-26 years.
@en
type
label
The impact of quadrivalent hum ...... active women aged 16-26 years.
@en
prefLabel
The impact of quadrivalent hum ...... active women aged 16-26 years.
@en
P2093
P50
P356
P1476
The impact of quadrivalent hum ...... active women aged 16-26 years.
@en
P2093
Amha Tadesse
Daron G Ferris
Darron R Brown
Eliav Barr
Elmar A Joura
Eng Hseon Tay
Evan R Myers
F Xavier Bosch
Frank J Taddeo
Gonzalo Perez
P304
P356
10.1086/597309
P407
P577
2009-04-01T00:00:00Z